The World’s Longest Standing & Definitive ADC Forum
Upcoming Meetings in the Series:
 |
4th ADC Target Selection Summit |
 |
15th World ADC London
|
 |
Novel Conjugates Summit
|
Your Annual Industry Touchpoint to Maximize the Therapeutic Index of Your ADC
Accelerate Your Antibody-Drug Conjugate Pipeline to Become a Front-Line Treatment
Your Annual Industry Touchpoint to Maximize the Therapeutic Index of Your ADC
Accelerate Your Antibody-Drug Conjugate Pipeline to Become a Front-Line Treatment
Thank you to our speakers, sponsors, and delegates who joined us in San Diego for the summit! If you are interested in the 2025 event, please get in touch at adc@hansonwade.com
Antibody-drug conjugates are receiving unrivalled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and Astellas’ PADCEV, all alongside a frenzy of companies entering the field and billion-dollar partnerships and M&As from Pfizer, AbbVie, J&J, Merck, Genmab, Ipsen and beyond, ADCs have firmly positioned themselves at the forefront of oncology R&D and dealmaking.
Returned as the industry’s definitive ADC forum from early discovery to late-phase manufacturing, the 15th World ADC San Diego was the world-leading, largest, and most comprehensive ADC-focused conference to maximize the therapeutic window of ADCs. Whether attendees just ventured into the ADC space or were an ADC guru, they left this meeting with the insight and connections needed to overcome their challenges and make impactful strides in their work.
Uniting over 1,200 ADC enthusiasts from field novices to long-standing KOLs including experts from Daiichi Sankyo, Pfizer, AbbVie, AstraZeneca, and ADC Therapeutics, World ADC San Diego was the annual community touchpoint to gain unparalleled knowledge across cutting-edge R&D, end-to-end development strategy, and global market trends to progress ADCs to new standard of care treatments in oncology and beyond.
Cutting-Edge, End-to-End Scientific Content for All Stages of ADC Development
From new members to long-standing experts in the ADC field, our program had attendees covered:
The 140+ World Class 2024 Speakers Included:
Ahsan Arozullah
Senior Vice President & Head, Oncology Development
Astellas Innovation Management LLC
Puja Sapra
Senior Vice President, Biologics Engineering & Oncology Targeted Discovery, Oncology R&D
AstraZeneca
Our 2024 Partners:
Lead Partner
Senior Partners
Partners
Exhibitors
Event Partners
About World ADC Series
The World ADC team ploughs its collective energy in to sourcing the insights you need. We investigate the most challenging problems facing the industry; source the leading experts who have game-changing solutions; and distil this into accessible formats of information exchange – for you. From globally leading conferences to webinars and industry reports, whatever the information you need, World ADC can offer you the insights you need to accelerate your ADC programs.
The value World ADC provides you is the power of insight and connections. Not artificial, and not short-lived. We nurture the right environments in which people can communicate problems and solutions; share novel data and forge networks across the industry that will make each of your endeavours more informed and more robust.
We share a common belief with the industry – that the potential of antibody drug conjugates is enormous. In the war against cancer, ADCs can be a game-changer and we know that the right insights and connections can sharpen the weapons that are in your arsenal.
Join us at the heart of the ADC community to improve your programmes and be part of the mission to develop better antibody drug conjugate drugs.
